Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis
Johnson B, Teply B, Kagemann C, McGuire B, Lombardo K, Jing Y, Langbo W, Epstein J, Netto G, Baras A, Matoso A, McConkey D, Gupta A, Ahuja N, Ross A, Pierorazio P, Comperat E, Hoffman-Censits J, Singla N, Patel S, Kates M, Choi W, Bivalacqua T, Hahn N. Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis. Bladder Cancer 2024, 10: 133-143. PMID: 39131872, PMCID: PMC11308648, DOI: 10.3233/blc-240008.Peer-Reviewed Original ResearchExpression of immune checkpointsClinical activityNeoadjuvant cisplatinImmune checkpointsT cellsIncreased expression of immune checkpointsTranscriptome RNA sequencingMuscle-invasive patientsPegfilgrastim 6 mgAggressive histologic subtypePathological complete responseUrothelial bladder cancerT cell genesBasal-squamousYpCR rateNeoadjuvant therapyComplete responseHistological subtypesSingle-institutionUrothelial cancerPrimary endpointUrothelial tumorsTumor biologyBladder cancerGrade 3
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply